ABSTRACT
A new and simple procedure was applied to detect bisphenol A (BPA) based on a BPA aptamer and its complementarystrand (Comp. Str.). An electrode was modified with a mixture of carboxylated multiwalled carbon nanotubes and chitosan.The Comp. Str. was immobilized on a modified-glassy carbon electrode (GCE) surface via covalent binding. After theincubation of the aptamer with the electrode surface, it could interact with the Comp. Str. In the presence of BPA, itsaptamer will interact with the analyte, resulting in some changes in the configuration and leading to separation from theelectrode surface. Due to the attached ferrocene (Fc) group on the 50 head of the aptamer, the redox current of Fc hasreduced. This aptasensor can sense the level of BPA in the linear range of 0.2–2 nM, with a limit of detection of 0.38 nMand a sensitivity of 24.51 lA/nM. The proposed aptasensor showed great reliability and selectivity. The acceptable selectivity is due to the specificity of BPA binding to its aptamer. The serum sample was used as a real sample; the aptasensorwas able to effectively recover the spiked BPA amounts. It can on-site monitor the BPA in serum samples withacceptable recoveries.
ABSTRACT
Despite current advances in multimodality therapies, such as surgery, radiotherapy, and chemotherapy, the outcome for patients with high-grade glioma remains fatal. Understanding how glioma cells resist various therapies may provide opportunities for developing new therapies. Accumulating evidence suggests that the main obstacle for successfully treating high-grade glioma is the existence of brain tumor stem cells (BTSCs), which share a number of cellular properties with adult stem cells, such as self-renewal and multipotent differentiation capabilities. Owing to their resistance to standard therapy coupled with their infiltrative nature, BTSCs are a primary cause of tumor recurrence post-therapy. Therefore, BTSCs are thought to be the main glioma cells representing a novel therapeutic target and should be eliminated to obtain successful treatment outcomes.
Subject(s)
Humans , Adult Stem Cells , Brain Neoplasms , Brain , Drug Therapy , Glioma , Radiotherapy , Recurrence , Stem CellsABSTRACT
La reprogramación de células somáticas para generar células madre pluripotentes inducidas (iPS), ha sido uno de los avances más importantes de la biología en los últimos años. La identificación de un grupo de factores de transcripción y más recientemente de algunos compuestos químicos que pueden inducir la pluripotencia en células somáticas, brinda una oportunidad única para el estudio de los mecanismos celulares y moleculares de la diferenciación celular y promete la posibilidad de generar células pluripotentes paciente-específicas para el tratamiento de múltiples enfermedades en protocolos terapia celular y medicina regenerativa...
Reprogramming of somatic cells to generate induced pluripotent stem cells (iPS), has been one of the most important advances in biology in recent years. The identification of a group of transcription factors and more recently of some chemical compounds that can induce pluripotency in somatic cells provides a unique opportunity to study cellular and molecular mechanisms of cell differentiation and promises the possibility of generating patient-specific pluripotent stem cells for the treatment of multiple diseases in protocols of cell therapy and regenerative medicine...
A reprogramação de células somáticas para gerar células-tronco pluripotentes induzidas (iPS), tem sido um dos mais importantes avanços na biologia nos últimos anos. A identificação de um conjunto de fatores de transcrição e, mais recentemente, de alguns compostos químicos que podem induzir pluripotência em células somáticas produzem uma oportunidade única para estudar os mecanismos celulares e moleculares da diferenciação celular e promete a capacidade de gerar células pluripotentes doente-específicas para o tratamento de doenças múltiplas nos protocolos de terapía celular e medicina regenerativa...